ITGAE and neoplasm: Whereas the co-expression of CD39 and CD103 has been suggested to be a marker of tumor antigen-specific TILs in solid tumors, in some researches including CRC, CD103+CD39+T cells have been suggested to be an immune marker to predict patient prognosis as well as response to ICB therapy (19–21).